非他汀类降脂药物的研究新进展

Research progress in non statin lipid-lowering drugs cancer

近年来,久坐不动的生活方式和肥胖流行病的兴起加剧了血脂异常等疾病的发病率,严重危害人类的身体健康。他汀类药物目前仍然是心血管疾病的一级预防和降脂的主要治疗方法,其安全性和有效性已得到充分证实。尽管他汀类药物治疗可显著降低低密度脂蛋白(LDL)水平,但仍有患者无法达到目标血脂或存在对他汀类药物的不良反应,故需要额外的非他汀类药物辅助治疗。本文通过对胆汁酸螯合剂(BAS)、贝特类药物、胆固醇吸收抑制剂、前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂、胆固醇脂转运蛋白(CETP)抑制剂等非他汀类调脂药物的作用机制、安全性和有效性等进行研究,以期为调脂方案提供选择。

In recent years,the sedentary lifestyle and the rise of the obesity epidemic have increased the incidence rate of diseases such as dyslipidemia,which seriously endangers people′s health.Statins are still the primary prevention of cardiovascular disease and the main treatment method for reducing blood lipid,and their safety and effectiveness have been fully confirmed.Although statins can significantly reduce the level of low density lipoprotein(LDL),some patients cannot reach the blood lipid goal of statins or have intolerance to the adverse reactions of statins,Therefore,additional non statin drugs are needed to assist in treatment.This review elucidates the research progress on the mechanism of action,safety and effectiveness of non statin lipid-lowering drugs such as bile acid sequestran(BAS),fibrates,cholesterol absorption inhibitors,proprotein convertase subtilisin/kexin 9(PCSK9)inhibitors and cholesteryl ester transfer protein(CETP)inhibitors,in order to provide a choice for lipid-lowering therapy.